Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
You aren't powerless in the face of what the market throws at you.
Gene editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks. It could help treat the 7,000 diseases caused by genetic disorders, most of which occur with gene mutation. Or, as noted by the Cleveland Clinic, when you have the wrong amount of genetic material. It’s even helped address a form of inherited blindness in patients, including children. According to Penn Medicine News, “nearly half reported measurable improvements
With the market struggling amid rising recession fears, now may be the ideal time to consider biotech stocks. First, the sector itself is a financially lucrative one. Last year, the ecosystem reached a valuation of $1.55 trillion. Between 2024 to 2030, the segment could expand at a compound annual growth rate (CAGR) of 13.96% to $3.88 trillion. Along this line of thinking, the current market fallout makes biotech stocks all the more intriguing. No matter what, society will always push for soluti
Investing guru Cathie Wood sees precision therapeutics as a massive growth market. She forecasts sales in the category can grow by a compound annual growth rate (CAGR) of 30% through 2030. Efficiencies could contribute $1.5 trillion to the enterprise value of companies pursuing these technologies. Over the next five years or so, gene-editing using CRISPR-based processes to target and cure rare diseases and chronic conditions will expand at a 46% CAGR. Wood seeks out opportunities to generate phe
CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.76% and 93.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July- -Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications- -Clinical trials opened for CTX112 in systemic lupus erythematosus (SLE) and for CTX131 in hematological malignancies- -Clinical trials ongoing for in vivo gene editing p
The biotech recently became a commercial-stage company.
We recently compiled a list of Ark Invest Stock Portfolio: Top 10 Picks. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against Ark Invest’s other stocks picks. If there’s one thing that can be said for sure, it’s that Cathie Wood’s investment approach is one of the […]
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.